Covaxin Commercialisation rights has been secured by Ocugen Inc. Ocugen and Bharat Biotech has entered into amended agreement to expand the US firm’s Co-development, Supply and Commercialization, and the exclusive territory of commercialisation of Covaxin, a Covid-19 vaccine of the Indian vaccine maker, to Mexico.
COVAXIN™️ can be an ideal vaccination option for Mexico at this stage of the pandemic. As a whole virion, inactivated vaccine, it elicits robust cellular immune memory to SARS-CoV-2 and Variants of Concern. It offers logistical advantages that could support vaccine access in hard-to-reach communities.
COVAXIN commercialisation rights for all of North America
Furthermore, according to a press statement on April 18, Ocugen under the agreement will have COVAXIN™️ commercialization rights for all of North America.
The Mexican authorities have made conquering the COVID-19 pandemic a major priority, said Ocugen Inc co-founder and chief executive officer Dr Shankar Musunuri, adding that they met Mexico’s secretary of foreign affairs, Marcelo Ebrard, in Delhi.
“Covaxin is currently under review by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) for emergency use among children between 2 and 18 years of age, and Ocugen is prepared to collaborate with the public health community to help their efforts,” said Dr Shankar Musunuri, viewing that Covaxin can be an ideal vaccination option for Mexico at this stage of the pandemic.
Bharat Biotech chairman and managing director Dr Krishna Ella said, “Covaxin is a safe and efficacious inactivated vaccine for all age groups as evident from its data from the global introduction.” Ella said the Indian vaccine innovator was fully supportive of team Ocugen in its endeavour to expedite technology transfer activities towards commercial-scale manufacturing of Covaxin in North America.
The license extension between Ocugen and Bharat Biotech with respect to commercialisation in Mexico includes the same profit share structure as in the United States, said the press statement.